{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:52:09Z","timestamp":1785523929936,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04477-4","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:06:51Z","timestamp":1785236811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the significance of CCNE1 overexpression in triple negative breast cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-7273","authenticated-orcid":false,"given":"Nigar Pelin","family":"Makas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin","family":"Belder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Akbulut-\u00c7al\u0131\u015fkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Saat\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin G\u00fclizar","family":"Ersan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filiz Susuz","family":"Alanyal\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"4477_CR1","doi-asserted-by":"crossref","unstructured":"J Alder, J Bitzer, (2002). Retrospective evaluation of the treatment for breast cancer: how does the patient\u2019s personal experience of the treatment affect later adjustment to the illness? Springer-Verlag 6(2): 91\u201397","DOI":"10.1007\/s00737-002-0151-5"},{"issue":"5","key":"4477_CR2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/sj.bjc.6605736","volume":"103","author":"SJ Dawson","year":"2010","unstructured":"Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. British J Cancer. 2010;103(5):668\u201375.","journal-title":"British J Cancer"},{"key":"4477_CR3","doi-asserted-by":"crossref","unstructured":"D G Hicks, S M Short, N L Prescott, S M Tarr, K A Coleman, et al., (2006). Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5\/6, and Overexpress HER2 or EGFR. Lippincott Williams & Wilkin 30(9): 1097\u20131104.","DOI":"10.1097\/01.pas.0000213306.05811.b9"},{"key":"4477_CR4","doi-asserted-by":"crossref","unstructured":"Fran\u00e7ois Bertucci, P.F., Nathalie Cervera, Benjamin Esterni, Fabienne Hermitte, et al. (2008). How basal are triple-negative breast cancers? 2008 Wiley-Liss, Inc 123(1): 236\u201340.","DOI":"10.1002\/ijc.23518"},{"key":"4477_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1186\/s12885-017-3726-2","volume":"17","author":"DA Melissa Quintero","year":"2017","unstructured":"Melissa Quintero DA, Menezes L, dos Reis C, Fernanda RA, et al. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer. BMC Cancer. 2017;17:727.","journal-title":"BMC Cancer"},{"key":"4477_CR6","doi-asserted-by":"crossref","unstructured":"E E Newton, L.M.a.H.L.M (2022). Molecular Targets of Triple-Negative Breast Cancer: Where Do WeStand?. Cancers 12: 482.","DOI":"10.3390\/cancers14030482"},{"key":"4477_CR7","first-page":"93","volume":"8","author":"LL Jo\u00eblle Collignon","year":"2016","unstructured":"Jo\u00eblle Collignon LL. H\u00e9l\u00e8ne Schroeder, Guy Jerusalem, Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer: Targets and Therapy. 2016;8:93\u2013107.","journal-title":"Breast Cancer: Targets and Therapy"},{"issue":"1","key":"4477_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12865-024-00635-x","volume":"25","author":"MW Shuaikang Pan","year":"2024","unstructured":"Shuaikang Pan MW, Jin H, Ning R, Zhang J, Han X. LCP1 correlates with immune infltration: a prognostic marker for triple-negative breast cancer. BMC Immunol. 2024;25(1):42.","journal-title":"BMC Immunol"},{"issue":"1","key":"4477_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41420-024-02091-3","volume":"10","author":"R Elango","year":"2024","unstructured":"Elango R, Radhakrishnan V, Rashid S, Al-Sarraf R, Akhtar M, Ouararhni K, et al. Long noncoding RNA profiling unveils LINC00960 as unfavorable prognostic biomarker promoting triple negative breast cancer progression. Cell Death Discov. 2024;10(1):333.","journal-title":"Cell Death Discov."},{"issue":"4","key":"4477_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.18632\/aging.100946","volume":"8","author":"SH Dongdong Fang","year":"2016","unstructured":"Dongdong Fang SH. Shi-Bing Su, Cyclin E1-CDK 2, a potential anticancer target. Aging (Albany NY). 2016;8(4):571\u20132.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"4477_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2013.09.011","volume":"50","author":"D Pils","year":"2013","unstructured":"Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, et al. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients. Eur J Cancer. 2013;50(1):99\u2013110.","journal-title":"Eur J Cancer"},{"issue":"11","key":"4477_CR12","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1002\/cncr.24987","volume":"116","author":"KN Naomi Nakayama","year":"2010","unstructured":"Naomi Nakayama KN, Shamima Y, Ishikawa M, Katagiri A, et al. Gene amplification CCNE1 Is related to poor survival and potential therapeutic target in ovarian cancer. Cancer. 2010;116(11):2621.","journal-title":"Cancer"},{"issue":"9","key":"4477_CR13","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/cncr.21767","volume":"106","author":"DG Rosen","year":"2006","unstructured":"Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer. 2006;106(9):1925.","journal-title":"Cancer"},{"issue":"3","key":"4477_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jmoldx.2010.11.020","volume":"13","author":"WW Lockwood","year":"2011","unstructured":"Lockwood WW, Stack D, Morris T, Grehan D, O\u2019Keane C, Stewart GL, et al. Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn. 2011;13(3):289.","journal-title":"J Mol Diagn"},{"issue":"1","key":"4477_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1053\/hupa.2001.21141","volume":"32","author":"R Donnellan","year":"2001","unstructured":"Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol. 2001;32(1):89\u201394. https:\/\/doi.org\/10.1053\/hupa.2001.21141.","journal-title":"Hum Pathol"},{"key":"4477_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nm0297-222","volume":"3","author":"P Porter","year":"1997","unstructured":"Porter P, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997;3:222.","journal-title":"Nat Med"},{"issue":"20","key":"4477_CR17","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1056\/NEJMoa021153","volume":"347","author":"K Keyomarsi","year":"2002","unstructured":"Keyomarsi K, Tucker S, Buchholz TA, Callister M, Ding Y, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347(20):1566.","journal-title":"N Engl J Med"},{"key":"4477_CR18","doi-asserted-by":"crossref","unstructured":"Jian Carrot-Zhang, N.C., Jeffrey S. Damrauer, Andrew D. Cherniack, Rameen Beroukhim, Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. 2020 Elsevier Inc., 2020. 37: p. 639\u2013654.","DOI":"10.1016\/j.ccell.2020.04.012"},{"issue":"5","key":"4477_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.15252\/emmm.201505891","volume":"8","author":"T Gruosso","year":"2016","unstructured":"Gruosso T, Mieulet V, Cardon M, Bourachot B, Kieffer Y, Devun F, et al. Chronic oxidative stress promotes H2AX proteindegradation and enhances chemosensitivity in breast cancer patients. EMBO Mol Med. 2016;8(5):527\u201349.","journal-title":"EMBO Mol Med"},{"issue":"11","key":"4477_CR20","doi-asserted-by":"publisher","first-page":"e27656","DOI":"10.1371\/journal.pone.0027656","volume":"6","author":"PF Renaud Sabatier","year":"2011","unstructured":"Renaud Sabatier PF, Adelaide J, Guille A, Borg JP, et al. Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS ONE. 2011;6(11):e27656.","journal-title":"PLoS ONE"},{"issue":"1","key":"4477_CR21","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1038\/s41598-021-83913-7","volume":"11","author":"KE Craven","year":"2021","unstructured":"Craven KE, Gokmen-Polar Y, Badve SS. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. Sci Rep. 2021;11(1):4691.","journal-title":"Sci Rep"},{"key":"4477_CR22","unstructured":"G Ciriello, M L Gatza, A H Beck, Tari A. King, TCGA Research Network, Charles M. Perou, (2015). Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Elsevier Inc 163: 506\u2013519."},{"issue":"10","key":"4477_CR23","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1093\/carcin\/bgt208","volume":"34","author":"SFM Colin Clarke","year":"2013","unstructured":"Colin Clarke SFM, Doolan P, et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carsinogenesis. 2013;34(10):2300.","journal-title":"Carsinogenesis"},{"issue":"1","key":"4477_CR24","first-page":"1008","volume":"15","author":"D Fumagalli","year":"2014","unstructured":"Fumagalli D, Blanchet-Cohen A, Brown D, et al. Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. BMC Article. 2014;15(1):1008.","journal-title":"BMC Article"},{"issue":"1","key":"4477_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14(1):128.","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"4477_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ijc.33283","volume":"148","author":"BG \u00c1d\u00e1m Nagy","year":"2020","unstructured":"\u00c1d\u00e1m Nagy BG. muTarget: a platform linking gene expression changes and mutation status in solid tumors. Int J Cancer. 2020;148(2):502\u201311.","journal-title":"Int J Cancer"},{"issue":"1","key":"4477_CR27","doi-asserted-by":"publisher","first-page":"4853632","DOI":"10.1155\/2021\/4853632","volume":"2021","author":"H Xie","year":"2021","unstructured":"Xie H, Lie B, Chang Y, Hou X, Zhang Y, et al. Selection and validation of reference genes for RT-qPCR analysis in Spinacia oleracea under abiotic stress. BioMed Res Intern. 2021;2021(1):4853632.","journal-title":"BioMed Res Intern"},{"key":"4477_CR28","doi-asserted-by":"crossref","unstructured":"Harry Towbin, T.S, Julian Gordon, (1979). Electrophoretic transfer of proteins from polyacrylamide gels tonitrocellulose sheets: Procedure and some applications. Communicated by V. Prelog 76(9): 4354.","DOI":"10.1073\/pnas.76.9.4350"},{"key":"4477_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/cdd.2015.53","volume":"22","author":"KG Wiman","year":"2015","unstructured":"Wiman KG, Soussi T. TP53: an oncogene in disguise. Cell Death Differ. 2015;22:1239\u201349.","journal-title":"Cell Death Differ"},{"key":"4477_CR30","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/carcin\/bgac015","volume":"43","author":"P Suman","year":"2022","unstructured":"Suman P, Mehta V, Craig AWB, Chander H. Wild-type p53 suppresses formin-binding protein-17 (FBP17) to reduce invasion. Carcinogenesis. 2022;43:494\u2013503.","journal-title":"Carcinogenesis"},{"key":"4477_CR31","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1186\/s13058-014-0503-x","volume":"16","author":"H Chander","year":"2014","unstructured":"Chander H, Brien CD, Truesdell P, Watt K, Meens J, et al. Toca-1 is suppressed by p53 to limit breast cancer cell invasion and tumor metastasis. Breast Cancer Res. 2014;16:3413.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"4477_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"IF Mantovani","year":"2019","unstructured":"Mantovani IF, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26(2):199\u2013212.","journal-title":"Cell Death Differ"},{"issue":"1","key":"4477_CR33","doi-asserted-by":"publisher","first-page":"624","DOI":"10.18632\/oncotarget.13483","volume":"8","author":"QS Xiaosheng Wang","year":"2017","unstructured":"Xiaosheng Wang QS. TP53 mutations, expression and interaction networks in human cancers. Oncotarget. 2017;8(1):624\u201343.","journal-title":"Oncotarget"},{"key":"4477_CR34","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4477_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.18388\/abp.2007_3233","volume":"54","author":"A Nauman","year":"2007","unstructured":"Nauman A, Turowska O, Poplawski P, Master A, Tanski Z, Puzianowska-Kuznicka M. Elevated cyclin E level in human clear cell renal cell carcinoma: possible causes and consequences. Acta Biochim Pol. 2007;54(3):602.","journal-title":"Acta Biochim Pol"},{"issue":"4","key":"4477_CR36","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0002-9440(10)65216-9","volume":"155","author":"JJ Del Pizzo","year":"1999","unstructured":"Del Pizzo JJ, Borkowski A, Jacobs SC, et al. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol. 1999;155(4):1129.","journal-title":"Am J Pathol"},{"key":"4477_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cancergencyto.2004.03.007","volume":"153","author":"R Nakayama","year":"2004","unstructured":"Nakayama R, et al. Amplification and overexpression of genes in 17p11.2~p12 in osteosarcoma. Elsevier-Cancer Genet Cytogenet. 2004;153:77\u201380.","journal-title":"Elsevier-Cancer Genet Cytogenet"},{"issue":"10","key":"4477_CR38","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1172\/JCI81568","volume":"126","author":"RA Jones","year":"2016","unstructured":"Jones RA, Robinson TJ, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. The J Clin Investig. 2016;126(10):3739\u201357.","journal-title":"The J Clin Investig"},{"issue":"2","key":"4477_CR39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/path.1247","volume":"199","author":"Y Dobashi","year":"2003","unstructured":"Dobashi Y, Jiang S, Shoji M, et al. Diversity in expression and prognostic significance of G1\/S cyclins in human primary lung carcinomas. J Pathol. 2003;199(2):208.","journal-title":"J Pathol"},{"issue":"3","key":"4477_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0002-9440(10)64592-0","volume":"157","author":"J Richter","year":"2000","unstructured":"Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol. 2000;157(3):787.","journal-title":"Am J Pathol"},{"issue":"6","key":"4477_CR41","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1158\/2767-9764.CRC-23-0496","volume":"4","author":"N Rustgi","year":"2024","unstructured":"Rustgi N, Wu S, Samec T, Walker P, Xiu J, Lou E, et al. Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer. Cancer Res Commun. 2024;4(6):1409.","journal-title":"Cancer Res Commun"},{"issue":"3","key":"4477_CR42","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.cell.2022.12.036","volume":"186","author":"J Zeng","year":"2023","unstructured":"Zeng J, Hills SA, Ozono E, Diffley JFX. Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication. Cell. 2023;186(3):542.","journal-title":"Cell"},{"issue":"1","key":"4477_CR43","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","volume":"24","author":"DC Fingar","year":"2004","unstructured":"Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24(1):200.","journal-title":"Mol Cell Biol"},{"key":"4477_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, Tao T, Li H, et al. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10:31.","journal-title":"Cell Biosci"},{"key":"4477_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/bjc.2016.198","volume":"115","author":"E Cocco","year":"2016","unstructured":"Cocco E, Lopez S, Black J, et al. Dual CCNE1\/PIK3CA targeting is synergistic in CCNE1-amplified\/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. Br J Cancer. 2016;115:311.","journal-title":"Br J Cancer"},{"key":"4477_CR46","doi-asserted-by":"crossref","unstructured":"George Au-Yeung, L.M., MBBS, and David D.L. Bowtell (2023). CCNE1 Amplification as a Therapeutic Target. Journal of Clinical Oncology 41(9): 1170.","DOI":"10.1200\/JCO.22.02267"},{"issue":"9","key":"4477_CR47","first-page":"1725","volume":"41","author":"F Siqing","year":"2022","unstructured":"Siqing F, Yao S, Yuan Y, et al. Multicenter Phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification. J Clinic Oncol. 2022;41(9):1725.","journal-title":"J Clinic Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04477-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04477-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04477-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:29:54Z","timestamp":1785518994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04477-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":47,"alternative-id":["4477"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04477-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":".O. Sahin is the co-founder and manager of OncoCube Therapeutics LLC, founder and president of LoxiGen, and member of the scientific advisory board of Coiled Therapeutics plc. The other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}